SABCS 2018 — Low-dose tamoxifen reduces recurrence of breast EIN


  • Univadis
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Low-dose tamoxifen halves the risk for new and recurrent disease among women with intraepithelial neoplasia (IEN) who have undergone surgery, according to data from a phase 3 trial.
  • TAM-01 included women with ductal carcinoma in situ (DCIS), lobular carcinoma in situ, and atypical ductal carcinoma.

Why this matters

  • Toxicity limits compliance with the standard 20-mg dose.
  • 5 mg tamoxifen did not significantly worsen menopausal symptoms or major adverse events vs placebo.

    Key results

    • Median follow-up, 5.1 years.
    • Risk for recurrence was 52% lower with tamoxifen vs placebo (5.5% vs 11.3%; 14 vs 28 events; HR, 0.48; P=.024)
    • Tamoxifen was tied to a decreased risk for contralateral breast cancer (CBC; 3 vs 12 cases; HR, 0.24; P=.018). 
    • 12 serious adverse events with tamoxifen vs 16 with placebo.
    • Rates of venous thromboembolism (VTE) were similar (1 case per group); there was 1 case of endometrial cancer in the tamoxifen group.
      • Expected rates with 20 mg/day tamoxifen would be 2.4 VTE events and 2.7 endometrial cancer cases.
    • 4 other neoplasms with tamoxifen, 6 with placebo.
    • No significant difference between groups for daily hot flash frequency (P=.05) or intensity (P=.18), vaginal dryness/intercourse pain (P=.57), or musculoskeletal pain/arthralgia (P=.84).

    Study design

    • Italian multicenter trial of 500 women with IEN randomly assigned to receive 5 mg/day tamoxifen (n=253) or placebo (n=247) for 3 years.
    • Funding: Italian Ministry of Health; Italian Association for Cancer Research; Italian League Against Cancer.
    • Dr DeCensi reports research funding from Indena SpA, Roche, Pfizer, Janssen, Novartis, Sanofi Aventis, Quintiles, Gilead, and Macrogenics.

    Limitations

    • Few CBC events.
    • 69%-70% DCIS.

    Please confirm your acceptance

    To gain full access to GPnotebook please confirm:

    By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

    Submit